Corium International, Inc. was a big mover last session, as the company saw its shares rise almost 12% on the day. The move came  after will present clinical results from a bioequivalence study of Corium's once-weekly Corplex Donepezil product candidate at the Alzheimer's Association International Conference 2017 (AAIC) in London, UK. This led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 25% in the past one-month time frame.

None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Corium International currently carries a Zacks Rank #2 (Buy), while its Earnings ESP is 0.00%.

Corium International, Inc. Price

 

Corium International, Inc. Price | Corium International, Inc. Quote

Another stock worth considering from the Medical – Generic Drugs space is Aquinox Pharmaceuticals, Inc. , carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is CORI going up? Or down? Predict to see what others think: Up or Down

Will You Make a Fortune on the Shift to Electric Cars?  

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>